Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3

Status

Terminated 4Completed 4Unknown 3

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 3Breast 1

Conditions

Melanoma 3Breast Neoplasms 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × montanide ISA 51 × Clear all
NCT02425306 2023-10-30

Mel63; CHAMP

University of Virginia

Phase 1/2 Terminated
48 enrolled 13 charts
Dermatologic

Melanoma

NCT00145158 2022-10-10

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Ludwig Institute for Cancer Research

Phase 1/2 Terminated
23 enrolled 8 charts
Dermatologic

Melanoma

NCT00365937 2019-03-06

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 1/2 Terminated
19 enrolled
Dermatologic

Melanoma

NCT00678509 2009-12-29

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Tokyo University

Phase 1/2 Terminated
14 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡